Good summary @laoshi. I agree it will be interesting how much market penetration they can get. Because although the Xprecia Prime is likely superior to the competition, in practice these features are likely relatively trivial, except perhaps in combination with the lower price point. I am however eagerly anticipating the release of the remaining wine testing products, as I believe they’re genuinely game changing.
@Chagsy I agree that the wine testing has great potential (Fructose test delayed but no further info) but when you look at the numbers in today's investor presentation the potential revenues from the health sector are much larger. The Lubricin technology opens up a whole range of point of care testing. I acknowledge that the lead time on these creating revenue is much longer and costlier but leveraging the technology in to diversified testing seems a sound strategy to me.
The animal diabetes monitoring seems like an easy win.
According to SimplyWallSt, UBIs new CEO John Sharman "serves as Investment Director of CVC Venture Managers Pty Limited." and according to UBIs website "Prior to joining MVP, John was responsible for all facets of the investment cycle during his 10-year service as Managing Director of a private equity firm, CVC Venture Managers."
On the 8th of July (shortly after Sharman was hired) UBI issued a ceasing to be substantial holder notice for CVC ltd - they sold 23,820,765 shares on market.
Does anyone know why CVC, a company Sharman is/was associated with would sell their shares shortly after he was hired by UBI? Is it as simple as avoiding a conflict of interest?
Hi Storge,
As per your recent straw regarding what's going on: my only guess would be the new CEO hire. John Sharman was with MVP - which has performed quite well while he was there and has joined UBI as of a week or so ago. I'll be keeping an eye on UBI solely because of Sharman but I have a feeling this is why the price has spiked recently.